Viewing Study NCT05950334


Ignite Creation Date: 2025-12-25 @ 2:20 AM
Ignite Modification Date: 2025-12-28 @ 12:04 AM
Study NCT ID: NCT05950334
Status: COMPLETED
Last Update Posted: 2025-08-22
First Post: 2023-07-10
Is NOT Gene Therapy: True
Has Adverse Events: False

Brief Title: FT522 With Rituximab in Relapsed/Refractory B-Cell Lymphoma (FT522-101)
Sponsor: Fate Therapeutics
Organization:

Study Modules

Identification Module Status Module Sponsor Collaborators Module Oversight Module Description Module Conditions Module Design Module Arms Interventions Module Outcomes Module Eligibility Module Contacts Locations Module